secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2022-12-20T23:59:59+00:00
Accession:  0001493152-22-036001
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics reports Q2/Q3 2022 revenue $4.2M each; appliance units up 28% and 20% YoY
--------------------------------------------------------------------------------

- Q2 revenue $4.2M, Q3 revenue $4.2M; net income not disclosed due to revenue recognition policy change.
- Appliance arches sold: 3,321 (Q2, +28% YoY) and 3,057 (Q3, +20% YoY).
- Gross margin fell to 62% (Q2) and 59% (Q3) from 81% and 70% in prior year periods.
- Cash and equivalents $6.7M at Sept 30, 2022; company targeting positive cash flow in 12-18 months.
- Operational highlights include TGA clearances for oral appliances in Australia and strategic billing partnership with Nexus Dental.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315222036001/0001493152-22-036001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315222036001/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-036001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer